This site is intended for healthcare professionals

CHMP positive for Keytruda as first-line treatment in metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer.- Merck Inc.

Read time: 1 mins
Last updated:28th Jun 2021
Published:17th Dec 2020
Condition: Microsatellite Instability-High (MSI-H) cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest